ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Comment by jjwilsonon Apr 20, 2018 8:52am

150 Views

Post# 27916082

RE:RE:PM300 offically in the books as another amyloid epitope

Yes. Why is this just showing up now and what is the significance of it being first (numerically) in the numbering sequence. Is it the best of the bunch and they have been holding news of it back for some reason (perhaps to develop the companion test)? Maybe it's the opposite - least important and least significant and therefore not disclosed to avoid diluting the news about the other epitopes.

Bullboard Posts

Visionstate set to leverage success in the U.S. market